好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Spanish Language Adaptation of the ALLFTD Genetic Counseling Protocol in Costa Rica
Aging, Dementia, and Behavioral Neurology
P3 - Poster Session 3 (11:45 AM-12:45 PM)
3-019

To standardize genetic counseling in Spanish for cases of autosomal dominant frontotemporal dementia (FTD) in Costa Rica.

Costa Rica is an upper-middle income country in Central America, with 5.2 million inhabitants. The prevalence of FTD is presumably like that of other countries. However, little is known about FTD in Costa Rica, and there are no reports of its genetics. Through a partnership with the ReDLat consortium, we aim to perform genetic testing on patients and their families. An initial challenge in this process is the lack of linguistically and culturally appropriate genetic counseling protocols. We therefore created a Spanish language adaptation of the ARTFL-LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) study’s genetic counseling Standard Operating Procedure (SOP).

A genetic counseling protocol was created by translating the ALLFTD SOP. Features of published strategies used for genetic counseling in Huntington’s disease in Latin America were incorporated. Psychiatric rating scales adopted by the Dominantly Inherited Alzheimer's Network were included into the protocol.

The protocol is divided into 6 sections: (1) Genetic counseling, (2) Mental health assessment of participants’ ability to process the results of testing, (3) Testing, (4) A one- to two-week delay to confirm with the participant whether to proceed with testing, (5) Results, (6) Follow-up. Psychiatric rating scales are applied in sections (2) and (6). The team necessary for the protocol includes at least one neurologist and one psychiatrist; but would ideally also include a psychologist and a genetic counselor.

The start of genetic testing for FTD and other dementias in Costa Rica requires standardization in genetic counseling. This protocol has been created as a first step in this initiative. Next steps include implementation and evaluation of the protocol.  This protocol could also be used in cases of suspected autosomal dominant Alzheimer's disease.

Authors/Disclosures
Sylvia Josephy, MD (Caja Costarricense de Seguro Social)
PRESENTER
Dr. Josephy has nothing to disclose.
Maria E. Godoy, MD Mrs. Godoy has nothing to disclose.
Agustin Ibanez, PhD (Universidad Adolfo Ibáñez, Latin American Brain Health Institute) Dr. Ibanez has nothing to disclose.
Adam L. Boxer, MD, PhD (University of California, San Francisco) An immediate family member of Dr. Boxer has received personal compensation for serving as an employee of Kaiser Permanente. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ono. Dr. Boxer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Oscotec. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Boxer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Arrowhead. Dr. Boxer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurocrine Biosciences. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Switch. Dr. Boxer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Arvinas. Dr. Boxer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alector. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Boxer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Transposon. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen . Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Boxer has stock in Alector. Dr. Boxer has stock in Arvinas. Dr. Boxer has stock in Neurovanda. The institution of Dr. Boxer has received research support from Biogen. The institution of Dr. Boxer has received research support from Eisai. The institution of Dr. Boxer has received research support from Regeneron. The institution of Dr. Boxer has received research support from NIH. The institution of Dr. Boxer has received research support from Bluefield Project-5. Dr. Boxer has received research support from Rainwater Charitable Foundation. Dr. Boxer has received research support from GHR Foundation. Dr. Boxer has received intellectual property interests from a discovery or technology relating to health care.
Howard J. Rosen, MD (UCSF) Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly . Dr. Rosen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alector. The institution of Dr. Rosen has received research support from NIH. The institution of Dr. Rosen has received research support from State of CA. Dr. Rosen has a non-compensated relationship as a Consultant with Prevail Therapeutics that is relevant to AAN interests or activities. Dr. Rosen has a non-compensated relationship as a consultant with Alchemab that is relevant to AAN interests or activities.
Leah K. Forsberg, PhD (Mayo Clinic) Ms. Forsberg has nothing to disclose.
Hilary Heuer (UCSF) Hilary Heuer has nothing to disclose.
Bradley F. Boeve, MD, FAAN (Mayo Clinic) Dr. Boeve has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Rainwater Charitable Foundation. The institution of Dr. Boeve has received research support from Alector. The institution of Dr. Boeve has received research support from EIP Pharma. The institution of Dr. Boeve has received research support from Transposon. The institution of Dr. Boeve has received research support from Cognition Therapeutics. Dr. Boeve has received publishing royalties from a publication relating to health care.
Jorge M. Leon Salas, MD Dr. Leon Salas has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Asofarma. Dr. Leon Salas has received research support from Alzheimer's Association .